Menu
Search
|

Menu

Close
X

Portola Pharmaceuticals Inc PTLA.OQ (NASDAQ Stock Exchange Global Select Market)

41.41 USD
-- (--)
As of Jun 18
chart
Previous Close 41.41
Open --
Volume --
3m Avg Volume 448,689
Today’s High --
Today’s Low --
52 Week High 67.10
52 Week Low 30.10
Shares Outstanding (mil) 65.83
Market Capitalization (mil) 2,642.88
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
23
FY16
36
FY15
12
EPS (USD)
FY18
-1.285
FY17
-4.769
FY16
-4.765
FY15
-4.347
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.18
Price to Sales (TTM)
vs sector
109.84
8.57
Price to Book (MRQ)
vs sector
8.85
4.35
Price to Cash Flow (TTM)
vs sector
--
22.78
Total Debt to Equity (MRQ)
vs sector
34.87
17.37
LT Debt to Equity (MRQ)
vs sector
34.87
12.92
Return on Investment (TTM)
vs sector
-90.28
13.17
Return on Equity (TTM)
vs sector
-139.93
15.15

EXECUTIVE LEADERSHIP

Hollings Renton
Independent Chairman of the Board, Since 2010
Salary: --
Bonus: --
Mardi Dier
Interim Co-President, Chief Financial Officer, Executive Vice President, Since 2018
Salary: $427,222.00
Bonus: $44,300.00
John Curnutte
Co-President, Executive Vice President Research and Development, Since 2018
Salary: $417,723.00
Bonus: $30,000.00
John Lawrence
Chief Executive Officer, Since 2018
Salary: $66,980.00
Bonus: --
John Moriarty
Executive Vice President, General Counsel, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

270 E Grand Ave Ste 22
SOUTH SAN FRANCISCO   CA   94080-4811

Phone: +1650.2446864

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

SPONSORED STORIES